These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 9242457)
1. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Nehmé A; Baskaran R; Aebi S; Fink D; Nebel S; Cenni B; Wang JY; Howell SB; Christen RD Cancer Res; 1997 Aug; 57(15):3253-7. PubMed ID: 9242457 [TBL] [Abstract][Full Text] [Related]
2. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Persons DL; Yazlovitskaya EM; Cui W; Pelling JC Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733 [TBL] [Abstract][Full Text] [Related]
4. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells. Okumura K; Shirasawa S; Nishioka M; Sasazuki T Cancer Res; 1999 May; 59(10):2445-50. PubMed ID: 10344756 [TBL] [Abstract][Full Text] [Related]
5. Determination of cell fate by c-Abl activation in the response to DNA damage. Kharbanda S; Yuan ZM; Weichselbaum R; Kufe D Oncogene; 1998 Dec; 17(25):3309-18. PubMed ID: 9916993 [TBL] [Abstract][Full Text] [Related]
6. c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Cong F; Goff SP Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13819-24. PubMed ID: 10570156 [TBL] [Abstract][Full Text] [Related]
7. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. Potapova O; Haghighi A; Bost F; Liu C; Birrer MJ; Gjerset R; Mercola D J Biol Chem; 1997 May; 272(22):14041-4. PubMed ID: 9162025 [TBL] [Abstract][Full Text] [Related]
8. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells. Helbig L; Damrot J; Hülsenbeck J; Köberle B; Brozovic A; Osmak M; Fiket Z; Kaina B; Fritz G J Biol Chem; 2011 Apr; 286(15):12991-3001. PubMed ID: 21324906 [TBL] [Abstract][Full Text] [Related]
9. Lack of c-Jun activity increases survival to cisplatin. Sánchez-Pérez I; Perona R FEBS Lett; 1999 Jun; 453(1-2):151-8. PubMed ID: 10403393 [TBL] [Abstract][Full Text] [Related]
10. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Raitano AB; Halpern JR; Hambuch TM; Sawyers CL Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11746-50. PubMed ID: 8524841 [TBL] [Abstract][Full Text] [Related]
11. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Kharbanda S; Ren R; Pandey P; Shafman TD; Feller SM; Weichselbaum RR; Kufe DW Nature; 1995 Aug; 376(6543):785-8. PubMed ID: 7651539 [TBL] [Abstract][Full Text] [Related]
12. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Kharbanda S; Pandey P; Yamauchi T; Kumar S; Kaneki M; Kumar V; Bharti A; Yuan ZM; Ghanem L; Rana A; Weichselbaum R; Johnson G; Kufe D Mol Cell Biol; 2000 Jul; 20(14):4979-89. PubMed ID: 10866655 [TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Gong JG; Costanzo A; Yang HQ; Melino G; Kaelin WG; Levrero M; Wang JY Nature; 1999 Jun; 399(6738):806-9. PubMed ID: 10391249 [TBL] [Abstract][Full Text] [Related]
14. Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. Pandey P; Raingeaud J; Kaneki M; Weichselbaum R; Davis RJ; Kufe D; Kharbanda S J Biol Chem; 1996 Sep; 271(39):23775-9. PubMed ID: 8798604 [TBL] [Abstract][Full Text] [Related]
15. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. Hayakawa J; Depatie C; Ohmichi M; Mercola D J Biol Chem; 2003 Jun; 278(23):20582-92. PubMed ID: 12663670 [TBL] [Abstract][Full Text] [Related]
16. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. Sutherland CL; Heath AW; Pelech SL; Young PR; Gold MR J Immunol; 1996 Oct; 157(8):3381-90. PubMed ID: 8871635 [TBL] [Abstract][Full Text] [Related]
17. Impaired jun-NH2-terminal kinase activation by ultraviolet irradiation in fibroblasts of patients with Cockayne syndrome complementation group B. Dhar V; Adler V; Lehmann A; Ronai Z Cell Growth Differ; 1996 Jun; 7(6):841-6. PubMed ID: 8780897 [TBL] [Abstract][Full Text] [Related]
18. Activated Ki-ras enhances sensitivity of ceramide-induced apoptosis without c-Jun NH2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human colon cancer cells. Ohmori M; Shirasawa S; Furuse M; Okumura K; Sasazuki T Cancer Res; 1997 Nov; 57(21):4714-7. PubMed ID: 9354428 [TBL] [Abstract][Full Text] [Related]
19. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Vasilevskaya IA; Rakitina TV; O'Dwyer PJ Mol Pharmacol; 2004 Jan; 65(1):235-43. PubMed ID: 14722256 [TBL] [Abstract][Full Text] [Related]
20. Activation of stress-activator protein kinase/c-Jun N-terminal kinase by the non-TPA-type tumor promoter palytoxin. Kuroki DW; Bignami GS; Wattenberg EV Cancer Res; 1996 Feb; 56(3):637-44. PubMed ID: 8564984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]